NEW YORK – Genetron Health said Thursday that it will work with Guizhou Province’s Dafang County authorities to lead a new effort in China called the "Early Screening for Regional Liver Cancer Prevention and Containment Demonstration Project."
Backed by the Central Committee of the Chinese Peasants and Workers Democratic Party and guided by China’s National Cancer Center, the program is a collective effort that will be carried out by the Dafang County Health Bureau, the People’s Hospital of Dafang, and Genetron Health.
Genetron, based in Beijing, will work with these partners to carry out early screening and facilitate diagnosis, treatment, follow-up screenings, and patient management for groups at high risk of liver cancer in the region. This will involve establishing a comprehensive cancer prevention and containment model.
The firm’s liver cancer screening assay, HCCscreen, is a genomic, blood-based test based on proprietary mutation detection technology. In recently released data, HCCscreen demonstrated 88 percent sensitivity and 93 percent specificity in a prospective cohort of 1,615 hepatitis B surface antigen-positive patients.
“In response to the government’s 'Healthy China 2030' campaign, we have made extensive efforts to build a three-dimensional cancer prevention and containment system,” Genetron CEO Sizhen Wang said in a statement.
Financial details of the collaboration were not disclosed.
The agreement follows a similar collaboration, between Genetron and China's Wuxi municipal government, last year.